These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28698350)

  • 21. A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight/obese patients with NAFLD: a multicenter randomized controlled trial in China.
    Liu Z; Jin P; Liu Y; Zhang Z; Wu X; Weng M; Cao S; Wang Y; Zeng C; Yang R; Liu C; Sun P; Tian C; Li N; Zeng Q
    Nutr J; 2024 Jun; 23(1):64. PubMed ID: 38872173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial.
    Razavi Zade M; Telkabadi MH; Bahmani F; Salehi B; Farshbaf S; Asemi Z
    Liver Int; 2016 Apr; 36(4):563-71. PubMed ID: 26503843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.
    de Piano A; de Mello MT; Sanches Pde L; da Silva PL; Campos RM; Carnier J; Corgosinho F; Foschini D; Masquio DL; Tock L; Oyama LM; do Nascimento CM; Tufik S; Dâmaso AR
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1313-24. PubMed ID: 22932160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial.
    Lorvand Amiri H; Agah S; Tolouei Azar J; Hosseini S; Shidfar F; Mousavi SN
    Clin Nutr; 2017 Dec; 36(6):1490-1497. PubMed ID: 27720403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Nutr Metab (Lond); 2018; 15():63. PubMed ID: 30263038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients.
    Zelber-Sagi S; Bord S; Dror-Lavi G; Smith ML; Towne SD; Buch A; Webb M; Yeshua H; Nimer A; Shibolet O
    World J Gastroenterol; 2017 Mar; 23(10):1881-1890. PubMed ID: 28348495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance, body composition, and fat distribution in obese children with nonalcoholic fatty liver disease.
    Yang HR; Chang EJ
    Asia Pac J Clin Nutr; 2016; 25(1):126-33. PubMed ID: 26965771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
    Trials; 2018 Nov; 19(1):634. PubMed ID: 30445988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
    Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of non-alcoholic fatty liver disease in obese children.
    Sartorio A; Del Col A; Agosti F; Mazzilli G; Bellentani S; Tiribelli C; Bedogni G
    Eur J Clin Nutr; 2007 Jul; 61(7):877-83. PubMed ID: 17151586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease.
    Torun E; Aydın S; Gökçe S; Özgen İT; Donmez T; Cesur Y
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():92-8. PubMed ID: 25910377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
    Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
    J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial.
    Sharifi S; Bagherniya M; Khoram Z; Ebrahimi Varzaneh A; Atkin SL; Jamialahmadi T; Sahebkar A; Askari G
    Phytother Res; 2023 Jun; 37(6):2217-2229. PubMed ID: 36799355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
    Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH
    Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.